Haematologica
HAEMATOL/2016/151035
Version 3

ZNF384-related fusion genes consist of a subgroup with a characteristic immunophenotype in childhood B-cell precursor acute lymphoblastic leukemia

Shinsuke Hirabayashi, Kentaro Ohki, Kazuhiko Nakabayashi, Hitoshi Ichikawa, Yukihide Momozawa, Kohji Okamura, Akinori Yaguchi, Kazuki Terada, Yuya Saito, Ai Yoshimi, Hiroko Ogata-Kawata, Hiromi Sakamoto, Motohiro Kato, Junya Fujimura, Moeko Hino, Akitoshi Kinoshita, Hiromi Kakuda, Hidemitsu Kurosawa, Keisuke Kato, Ryosuke Kajiwara, Koichi Moriwaki, Tsuyoshi Morimoto, Kozue Nakamura, Yasushi Noguchi, Tomoo Osumi, Kazuo Sakashita, Junko Takita, Yuki Yuza, Koich Matsuda, Teruhiko Yoshida, Kenji Matsumoto, Kenichiro Hata, Michiaki Kubo, Yoichi Matsubara, Takashi Fukushima, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara, and Nobutaka Kiyokawa

Disclosures: 1. This work was supported in part by a Health and Labour Sciences Research Grant (3rd-term comprehensive 10-year strategy for cancer control H22-011), the Grant of the National Center for Child Health and Development (26-20), and the Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO, 10-41, -42, -43, -44, -45), and Biobank Japan project funded by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Agency for Medical Research and Development (AMED), and the Practical Research for Innovative Cancer Control from AMED. These funding sources played no role in the collection, analysis, or interpretation of the results, or in the writing of the manuscript and decision to submit it. 2. The authors had no financial relationships with commercial entities. 3. EP300-ZNF384 is patent pending in Japan and other countries as a new diagnostic procedure by NK, KM, and HI.

Contributions: S.H, K.O., M.K., T.Y., K.M., K.H., M.K., Y.M., K.K., A.M., A.O., and N.K. designed the study. M.K., J.F., M.H., A.K., H.K., K.K., R.K., K.M., T.M., K. N., Y.N., T.O., K.S., J.T., and Y.Y. prepared clinical materials, collected and analyzed clinical information. K.N., Y.M., H.S., K.M., T.Y., and M.K. prepared the library and performed next-generation sequencing. H.I., K.O., H.O, H.S., and T.Y. performed bioinformatics analyses of the sequencing data. S.H., K.O., A.Y., K.T., Y.S., A.Y., T.F., and N.K. performed the experiments for validation of the genetic abnormalities and immunophenotyping. S.H., K.O., and N.K. analyzed the data and generated figures and tables. S.H., K.O., M.K., A.M., and N.K. wrote the manuscript. N.K. organized the entire project. All authors critically reviewed and revised the manuscript.